A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

and allows companies to make and distribute a product during a public health emergency while the FDA continues to review a ...

Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant, has confirmed high efficacy and ...

dose of Novavax' Matrix-M adjuvant, used to boost the immune response to the R21 antigen. Protective efficacy was 70% in the low-dose group and 80% in the high-dose group, answering concerns that ...